share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  07/18 08:01
Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has announced a new securities issue on July 18, 2024. The company, listed under the ASX issuer code ATH, plans to issue a total of 75,220,800 ordinary fully paid shares at an issue price of AUD 0.00540 per share. The purpose of the issue is to support further research and development activities and provide ongoing working capital. The issue will proceed without the need for security holder approval, utilizing the company's additional 10% placement capacity under listing rule 7.1A, chosen for its cost-effectiveness and timing benefits over other methods such as a pro rata issue or a security purchase plan. The newly issued securities will rank equally with existing securities and are not subject to any restrictions or voluntary escrow.
Alterity Therapeutics Limited, a development stage enterprise, has announced a new securities issue on July 18, 2024. The company, listed under the ASX issuer code ATH, plans to issue a total of 75,220,800 ordinary fully paid shares at an issue price of AUD 0.00540 per share. The purpose of the issue is to support further research and development activities and provide ongoing working capital. The issue will proceed without the need for security holder approval, utilizing the company's additional 10% placement capacity under listing rule 7.1A, chosen for its cost-effectiveness and timing benefits over other methods such as a pro rata issue or a security purchase plan. The newly issued securities will rank equally with existing securities and are not subject to any restrictions or voluntary escrow.
Alterity Therapeutics有限公司是一家处于发展阶段的企业,于2024年7月18日宣布了一项新的证券发行计划。该公司的股票代码为ATH,计划发行75220800股普通全额支付股份,每股发行价格为aud 0.00540。本次发行的目的是支持进一步的研究和开发活动,并提供持续的营运资本。该发行将在不需要股东批准的情况下进行,利用公司根据7.1A规则的额外10%配售比例,选择此方法是因为其成本效益和时间效益优于其他方法,例如比例发行或证券购买计划。新发行的证券与现有证券排名相同,不受任何限制或自愿托管。
Alterity Therapeutics有限公司是一家处于发展阶段的企业,于2024年7月18日宣布了一项新的证券发行计划。该公司的股票代码为ATH,计划发行75220800股普通全额支付股份,每股发行价格为aud 0.00540。本次发行的目的是支持进一步的研究和开发活动,并提供持续的营运资本。该发行将在不需要股东批准的情况下进行,利用公司根据7.1A规则的额外10%配售比例,选择此方法是因为其成本效益和时间效益优于其他方法,例如比例发行或证券购买计划。新发行的证券与现有证券排名相同,不受任何限制或自愿托管。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息